| UniProt ID | HGFA_HUMAN | |
|---|---|---|
| UniProt AC | Q04756 | |
| Protein Name | Hepatocyte growth factor activator | |
| Gene Name | HGFAC | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 655 | |
| Subcellular Localization | Secreted. Secreted as an inactive single-chain precursor and is then activated to a heterodimeric form. | |
| Protein Description | Activates hepatocyte growth factor (HGF) by converting it from a single chain to a heterodimeric form.. | |
| Protein Sequence | MGRWAWVPSPWPPPGLGPFLLLLLLLLLLPRGFQPQPGGNRTESPEPNATATPAIPTILVTSVTSETPATSAPEAEGPQSGGLPPPPRAVPSSSSPQAQALTEDGRPCRFPFRYGGRMLHACTSEGSAHRKWCATTHNYDRDRAWGYCVEATPPPGGPAALDPCASGPCLNGGSCSNTQDPQSYHCSCPRAFTGKDCGTEKCFDETRYEYLEGGDRWARVRQGHVEQCECFGGRTWCEGTRHTACLSSPCLNGGTCHLIVATGTTVCACPPGFAGRLCNIEPDERCFLGNGTGYRGVASTSASGLSCLAWNSDLLYQELHVDSVGAAALLGLGPHAYCRNPDNDERPWCYVVKDSALSWEYCRLEACESLTRVQLSPDLLATLPEPASPGRQACGRRHKKRTFLRPRIIGGSSSLPGSHPWLAAIYIGDSFCAGSLVHTCWVVSAAHCFSHSPPRDSVSVVLGQHFFNRTTDVTQTFGIEKYIPYTLYSVFNPSDHDLVLIRLKKKGDRCATRSQFVQPICLPEPGSTFPAGHKCQIAGWGHLDENVSGYSSSLREALVPLVADHKCSSPEVYGADISPNMLCAGYFDCKSDACQGDSGGPLACEKNGVAYLYGIISWGDGCGRLHKPGVYTRVANYVDWINDRIRPPRRLVAPS | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 48 | N-linked_Glycosylation | RTESPEPNATATPAI CCCCCCCCCCCCCCC | 48.54 | UniProtKB CARBOHYD | |
| 70 | O-linked_Glycosylation | VTSETPATSAPEAEG ECCCCCCCCCCCCCC | 26.99 | OGP | |
| 92 | O-linked_Glycosylation | PPPRAVPSSSSPQAQ CCCCCCCCCCCHHHH | 35.93 | OGP | |
| 94 | O-linked_Glycosylation | PRAVPSSSSPQAQAL CCCCCCCCCHHHHHC | 50.83 | OGP | |
| 95 | O-linked_Glycosylation | RAVPSSSSPQAQALT CCCCCCCCHHHHHCC | 23.99 | OGP | |
| 113 | Methylation | RPCRFPFRYGGRMLH CCCCCCCEECCEEEE | 29.44 | 30759923 | |
| 130 | Methylation | TSEGSAHRKWCATTH CCCCCHHCEECCCCC | 33.61 | 30759929 | |
| 290 | N-linked_Glycosylation | DERCFLGNGTGYRGV CCCEECCCCCCCCCC | 47.18 | 18638581 | |
| 382 | O-linked_Glycosylation | LSPDLLATLPEPASP CCHHHHHCCCCCCCC | 42.70 | OGP | |
| 468 | N-linked_Glycosylation | VLGQHFFNRTTDVTQ EEEEHHHCCCCCHHH | 39.17 | 18077410 | |
| 475 | N-linked_Glycosylation | NRTTDVTQTFGIEKY CCCCCHHHHCCCCCC | 34.38 | 16335952 | |
| 482 | Phosphorylation | QTFGIEKYIPYTLYS HHCCCCCCCCEEEEE | 8.37 | 22817900 | |
| 485 | Phosphorylation | GIEKYIPYTLYSVFN CCCCCCCEEEEECCC | 10.38 | 22817900 | |
| 492 | N-linked_Glycosylation | YTLYSVFNPSDHDLV EEEEECCCCCCCCEE | 32.77 | UniProtKB CARBOHYD | |
| 546 | N-linked_Glycosylation | GWGHLDENVSGYSSS CCCCCCCCCCCCCHH | 32.68 | UniProtKB CARBOHYD | |
| 569 | Phosphorylation | VADHKCSSPEVYGAD HHCCCCCCCHHCCCC | 34.25 | 24505115 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of HGFA_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of HGFA_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of HGFA_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
Oops, there are no PPI records of HGFA_HUMAN !! | ||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| N-linked Glycosylation | |
| Reference | PubMed |
| "Structural insight into distinct mechanisms of protease inhibition byantibodies."; Wu Y., Eigenbrot C., Liang W.C., Stawicki S., Shia S., Fan B.,Ganesan R., Lipari M.T., Kirchhofer D.; Proc. Natl. Acad. Sci. U.S.A. 104:19784-19789(2007). Cited for: X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 373-655 IN COMPLEX WITHANTIBODY, GLYCOSYLATION AT ASN-468, AND DISULFIDE BONDS. | |
| "Glycoproteomics analysis of human liver tissue by combination ofmultiple enzyme digestion and hydrazide chemistry."; Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; J. Proteome Res. 8:651-661(2009). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-468, AND MASSSPECTROMETRY. | |
| "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,hydrazide chemistry, and mass spectrometry."; Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,Moore R.J., Smith R.D.; J. Proteome Res. 4:2070-2080(2005). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-468, AND MASSSPECTROMETRY. | |